Patent intelligence · US
US 11311549
Corticotropin releasing factor receptor antagonists
Corticotropin releasing factor receptor antagonists
Patent details — US 11311549
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 26, 2022
- Expiration
- Apr 21, 2042
- Applicant
- SPRUCE BIOSCIENCES, INC.
- Claims
- 21
- CPC classes
- A61K, A61K31/5377, A61K31/573, A61K9/14
Quick answer
US 11311549 (Corticotropin releasing factor receptor antagonists) is held by SPRUCE BIOSCIENCES, INC.. Status: granted. Granted Apr 26, 2022. Expires Apr 21, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SPRUCE BIOSCIENCES, INC.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/5377, A61K31/573, A61K9/14, A61K9/48, A61K9/4825
More from SPRUCE BIOSCIENCES, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12115166
Corticotropin releasing factor receptor antagonists
granted -
US 12098152
Methods and compositions for treating polycystic ovary syndrome
granted -
US 11858932
Methods and compositions for treating polycystic ovary syndrome
granted -
US 11351177
Corticotropin releasing factor receptor antagonists
granted -
US 11344557
Corticotropin releasing factor receptor antagonists
granted -
US 11304950
Methods for treating testicular and ovarian adrenal rest tumors
granted -
US 11007201
Corticotropin releasing factor receptor antagonists
granted
Frequently asked questions
What is US patent 11311549?
US 11311549 (Corticotropin releasing factor receptor antagonists) is held by SPRUCE BIOSCIENCES, INC.. Status: granted. Granted Apr 26, 2022. Expires Apr 21, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11311549?
SPRUCE BIOSCIENCES, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does US 11311549 expire?
Our index shows an expiration date of Apr 21, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.